EJEvelina Jörtsö

Evelina Jörtsö

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Evelina Jörtsö has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Combined Assessment of HPV and p16 Optimizes Clinical Decision‐Making in Head and Neck Cancer of Unknown Primary

    by Evelina Jörtsö, Anders Näsman, Igor Schliemann, Mark Zupancic, Lars Sivars, Tina Dalianis, Linda Marklund, Rusana Bark

    Background: Human papillomavirus‐associated oropharyngeal squamous cell carcinoma (HPV+ OPSCC) is increasing in Sweden with implications for both the incidence and management of HPV+ head and neck cancer of unknown primary (HNCUP). In OPSCC, the combined presence of HPV DNA (HPV DNA+) and p16 INK4a (p16+) overexpression has been shown to provide superior prognostic information compared with either marker alone. In this study, we therefore aimed to assess whether the prognostic impact of HPV DNA and p16 concordance/discordance in HNCUP mirrors that observed in OPSCC, within a high HPV‐prevalent and low smoking population. Methods: In this retrospective population‐based cohort of 141 patients with HNCUP diagnosed at Karolinska University Hospital between 2000 and 2024, 128 had complete HPV DNA and p16 data and were included in analyses. Results: Consistent with previous findings in OPSCC, combined assessment of HPV DNA and p16 provided superior prognostic stratification compared with either marker alone. Nevertheless, HPV DNA+ as a single marker showed a prognostic impact almost comparable to that of combined HPV DNA+/p16+ status, while p16+ alone, although associated with some prognostic value, was less informative. HPV DNA‐negative disease was associated with poor prognosis irrespective of p16 status. Conclusions: The data suggest that combined assessment of HPV DNA and p16 is superior in HPV‐associated HNCUP. However, in settings where a single test must be chosen, and especially in areas with high prevalence of HPV + OPSCC, HPV DNA is preferable to p16. Such a strategy could simplify diagnostic workflows while still enabling effective risk stratification and supporting tailored patient management.

  • Open Access

    Age and tumour presentations differ between HPV type 16 positive and other high‐risk HPV type‐positive oropharyngeal squamous cell carcinomas in a Swedish cohort of 2000–2022

    by Anders Näsman, Madeleine Birgersson, Tobias Näsman, Evelina Jörtsö, Mark Zupancic, Rusana Bark, Linda Marklund, Tina Dalianis

    The incidence of human papillomavirus positive oropharyngeal squamous cell carcinoma (HPV+ OPSCC) has increased the past decades. Initial reports disclosed that HPV type 16 (HPV16) was predominant and that patients with HPV+ OPSCC were generally younger and had a better prognosis than those with HPV negative (HPV−) OPSCC. However, recent reports suggest that age differences between patients with HPV+ and HPV−OPSCC are less pronounced and that other high‐risk HPV types (HR‐HPV) are becoming more common. Here, we therefore investigated whether there were age differences between patients with HPV16‐positive and other HR‐HPV type positive OPSCC. During 2000–2022, in the Stockholm–Gotland‐Region, Sweden, 1681 patients with OPSCC tested for the presence of common mucosal HPV types were included. Among these, 1180 cases had a HR‐HPV type infection, with 1032 identified as HPV16 and 148 as other HR‐HPV types; one with a low‐risk HPV type infection; and 500 classified as HPV−. Patients with HPV+ OPSCC were significantly younger than those with HPV− OPSCC (mean 63 vs. 66.5, p <.001). Among patients with HPV+ OPSCC, those diagnosed with HPV16 were significantly younger than those with other HR‐HPV types (mean 61.1 vs. 64.5, p < 0.001). These age differences were present irrespective of sex, but patients with HPV16‐positive OPSCC were significantly more likely to present with smaller tumours upon diagnosis ( p = 0.002). Moreover, notably, statistically significant age differences between HPV16 and other HR‐HPV types were mainly observed in the more recent years (2010–2022). To conclude, the increasing influence of HR‐HPV types other than HPV16 in OPSCC warrants further investigation.


  • Open Access

    Fine needle aspiration cytology including the analysis of human papilloma virus (HPV) DNA enhances the diagnostic workup of solitary cystic neck lesions in a population with a high incidence of HPV positive oropharyngeal cancer

    by Evelina Jörtsö, Linda Marklund, Martin Harper Hysek, Anders Näsman, Lalle Hammarstedt-Nordenvall, Mathias Von Beckerath, Tina Dalianis, Rusana Bark

    Background and purpose: Distinguishing branchial cleft cysts (BrCCs) from cystic metastases of human papillomavirus (HPV) positive tonsillar or base of tongue squamous cell carcinoma and cancer of unknown primary (CUP) is challenging. Fine needle aspiration cytology (FNAC) from cystic metastasis can be nonrepresentative, while reactive squamous cells from BrCC can be atypical. It is unclear whether benign characteristics and the absence of HPV-DNA in FNAC can enhance distinguishing BrCC from a cystic metastasis; therefore, we investigated here. Patients/materials and methods: Morphology and HPV-DNA in FNAC were reevaluated preoperatively and correlated to final diagnosis of 304 BrCC and CUP patients at Karolinska University Hospital during 2016-2023. Results and interpretation: All 176 cases finally diagnosed as BrCC were HPV-DNA negative in the preoperative FNAC. HPV-DNA was present in 100/128 (78.1%) of the FNAC with a solitary cystic neck metastasis and in 3/3 CUPs separately investigated on surgical specimens, which is distributed in 40/58 (69.0%) CUP, 40/41 (97.6%) tonsillar cancer, 21/22 (95.5%) base of tongue cancer, 2/2 uterine cervical cancer, and 0/5 non-HPV-related cancers. Interpretation: All cases with final BrCC diagnosis were HPV-DNA negative in FNAC. HPV-DNA was only present in FNAC of malignant cystic neck masses of HPV-related tumors or CUP. The data suggest that HPV-DNA analysis in FNAC enhances the diagnostics of cystic masses of the neck. A FNAC with a benign morphology and the absence of HPV-DNA indicated a BrCC, while an HPV-DNA positive aspirate irrespective of morphology suggested an HPV-DNA positive cancer or CUP.